the university of oxford spinoff that designed astrazeneca plc’s covid19 vaccine is seeking a valuation as high as 613 million in its initial public offering in the us a move to help fund trials for new directions in cancer and other diseases vaccitech plc is set to offer 65 million american depository shares for as much as 18 each and will be listed on the nasdaq stock exchange according to a filing with the us securities and exchange commission the company which will trade under the vacc ticker will use the proceeds to advance the development of vaccines for hepatitis b virus human papillomavirus and prostate cancer